Crohn's disease (CD) is a potentially debilitating, chronic inflammatory disorder of the gastrointestinal tract. Moreover, current medications for this disorder tend to be broad-spectrum immunosuppressive agents with the potential for profound side effects. Thus there is a strong rationale to develop less toxic therapeutic options for CD, particularly in pediatric patients who may receive decades of potent immunosuppressive therapy. Although the precise etiology of CD remains unclear, altered epithelial function plays a key role in its pathogenesis. Therefore, the long-term goal of this research is to develop safer therapies for CD that augment intestinal epithelial function, as opposed to suppressing the immune system. Intestinal stem cells (ISCs) located at the base of intestinal crypts play a central role governing proliferation and differentiation of the gut epithelium. Although host pathways that regulate ISC function are progressively being elucidated, the effects of exogenous factors on ISC biology are poorly understood. In particular, the precise influences of the commensal enteric microbiota on ISC biology have not been characterized. Hence, the objective of the current proposal is to elucidate how the gut microbiota modulates ISC function. This objective will be achieved by testing the central hypothesis of this study, namely that the intestinal microbiota is a key regulator of ISC maintenance and proliferation. This hypothesis has been formulated based upon supporting preliminary data generated by the applicant, and will be tested via two specific aims. First, the role of the intestinal microbiota in regulating IS biology will be examined in healthy mice. This will be accomplished using established flow cytometry approaches, as well as complementary in vitro and in vivo techniques to compare ISC function in conventional (CV) versus germ-free (GF) mice. Second, the role of Paneth cells (PCs) as critical mediators of microbial-ISC interactions will be explored.
This aim i s built upon the rationale that PCs are a key component of the ISC niche, and are able to directly sense commensal gut bacteria. To accomplish this aim, established techniques for isolating PCs and ISCs will be used to assess the ability of GF versus CV PCs to support ISC growth in vitro. These data will be enhanced by in vivo characterization of ISC function in Irgm1-/- mice, which have clear PC abnormalities. The proposed approach is innovative because it focuses on a novel regulatory role for the gut microbiota, namely its ability to modulate PC niche signaling to the ISC compartment. This is in contrast to previous work that has concentrated on the role of the microbiota as a regulator of PC antimicrobial function. This research is significant because it is expected to lead to the development of microbial modulation strategies that will allow for the manipulation of ISC function for therapeutic purposes. Ultimately, this has the potential to minimize immunotoxic therapies for patients with CD, while concomitantly promoting mucosal healing. Importantly, the data and techniques established through this proposal will form the foundation for further independent studies that define the mechanisms by which intestinal bacteria regulate ISC biology.

Public Health Relevance

The proposed research is relevant to public health because it will increase the understanding of how resident gut bacteria fortify the epithelial lining of the intestines through their influences on intestinal stem cells. This will allow for the development o safer therapies for a spectrum of gastrointestinal disorders including Crohn's disease, which affects more than 500,000 patients in the United States alone, and leads to frequent hospitalizations, surgeries, missed work and school, and substantial health care costs (approximately $3.6 billion annually). Manipulating gut bacteria to enhance intestinal stem cell function has the potential to provide novel approaches to numerous gastrointestinal disorders in which the epithelial barrier is compromised.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Research Grants (R03)
Project #
1R03DK104005-01
Application #
8808509
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Podskalny, Judith M,
Project Start
2015-01-01
Project End
2016-12-31
Budget Start
2015-01-01
Budget End
2015-12-31
Support Year
1
Fiscal Year
2015
Total Cost
$76,000
Indirect Cost
$26,000
Name
University of North Carolina Chapel Hill
Department
Pediatrics
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Schoenborn, Alexi A; von Furstenberg, Richard J; Valsaraj, Smrithi et al. (2018) The enteric microbiota regulates jejunal Paneth cell number and function without impacting intestinal stem cells. Gut Microbes :1-14
Rogala, Allison R; Schoenborn, Alexi A; Fee, Brian E et al. (2018) Environmental factors regulate Paneth cell phenotype and host susceptibility to intestinal inflammation in Irgm1-deficient mice. Dis Model Mech 11:
Kumar, Pawan; Monin, Leticia; Castillo, Patricia et al. (2016) Intestinal Interleukin-17 Receptor Signaling Mediates Reciprocal Control of the Gut Microbiota and Autoimmune Inflammation. Immunity 44:659-671
Greer, Renee L; Dong, Xiaoxi; Moraes, Ana Carolina F et al. (2016) Akkermansia muciniphila mediates negative effects of IFN? on glucose metabolism. Nat Commun 7:13329